SenzaGen AB has attracted support from LU Innovation System AB to promote commercialization

Press release

SenzaGen AB has attracted support from LU Innovation System AB to promote commercialization

2014-11-17, Lund, Sweden

SenzaGen AB announces that LU Innovation System AB (LUIS) invests in the company.

SenzaGen AB, a diagnostic company working to replace animal testing, is based on research at the Department of Immunotechnology at Lund University. The company provides in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

LU Innovation System AB (LUIS) has since 1999 been involved in spinning out 69 companies based on research from Lund University. The portfolio has now increased by the investment in SenzaGen AB.

“We have a strong connection to Lund University and the investment by LUIS acknowledges our work and provides us with the ability to take the next important steps in our commercialization strategy,” says Anki Malmborg Hager, CEO of SenzaGen AB.

“We are very pleased of being a partner in Senzagen, which we believe has a great commercial potential. The fact that their technology can replace animal experiments doesn´t make it worse”, says Linus Wiebe, Innovation Director Lund University and CEO LU Innovation System.

The company´s first product, a skin sensitization test of chemicals, is already on the market, and the company is working on next generation products that will address other types of sensitizers and other routes of exposure. Based on the demand from the market the company is now gearing up its commercial operations and prepares for the launch of further products.

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will make in vitro testing a real option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB

+46 768 284822

Linus Wiebe, Director of Innovation, LU Innovation Systems AB

0733- 451 240

About Us

About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.


Documents & Links